Tabula Rasa HealthCare and Landmark to Improve Patient

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
58
Tabula Rasa HealthCare and Landmark to Improve Patient Outcomes in California and New York  

MOORESTOWN, N.J. and HUNTINGTON BEACH, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare , Inc. (NASDAQ: TRHC ), a healthcare technology company disrupting the field of medication safety, has licensed the use of its medication risk mitigation platform, MedWise Advisor® , to Landmark, a leading national medical group focused exclusively on the most chronically ill patients.

TRHC Chairman and CEO, Calvin H. Knowlton, PhD, commented, “We look forward to this new partnership with Landmark. This marks the first time Tabula Rasa will license the use of its platform for other clinicians to use in improving therapeutic outcomes. The new application of our solution further proves the flexibility of MedWise Advisor®, and provides a model to address the demand in our pipeline.

This partnership will allow us to expand our services to new and broader markets where we will not only be able to counteract one of the most avoidable causes of death and unintended medical injuries, but also continue to deliver on our goal of improving patient outcomes and lowering costs by reducing the occurrence of adverse drug events.”

Landmark is teaming up with Tabula Rasa to deploy the MedWise Advisor® platform, allowing Landmark clinicians to identify opportunities to improve the safety of their members’ medication profiles. Tabula Rasa’s pharmacist-staffed call centers also will provide “as-needed” clinical support to Landmark’s clinicians. First phase of the program will be launched by Landmark in two of its markets, California and New York.

“Tabula Rasa’s mission clearly aligns with ours,” said Landmark’s Chief Medical Officer, Dr. Michael Le. “Our patients are often on many different medications with the potential for complex interactions and unintended risk. Our Phase One engagement with Tabula Rasa will allow us to proactively identify patients with elevated risk profiles, and more importantly, enable our clinical staff to intervene and improve the patient’s medication regimen before any incident occurs.”

Dr. Le continued, “The ultimate goal of our collaboration is to use Tabula Rasa’s medication decision support tools to help reduce unnecessary hospitalizations and visits to the emergency room within our population, and to keep our patients healthier, with improved quality of life, at home.”

About Landmark Landmark is helping people age in place, with quality and dignity in their home. Their community-based, physician-led clinical teams are specialized in house calls and deliver medical, behavioral, social and palliative care to individuals with multiple chronic conditions, when and where it’s needed – 24 hours a day, 7 days a week. Their team of mobile clinicians collaborate with patients’ families, caregivers and other medical providers to bring coordinated world-class healthcare to people of any class. Learn more at LandmarkHealth.org.

About Tabula Rasa HealthCare Tabula Rasa HealthCare (NASDAQ: TRHC ) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.  Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit: www.trhc.com .

Contact:                                                                                                                               Media Dianne Semingson dsemingson@TRHC.com T: 215-870-0829 Investors Bob East or Asher Dewhurst Westwicke Partners 443-213-0500 tabularasa@westwicke.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 8

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading

Top 5 Most Recently Viewed Articles

HeartCore's Journey: From Nasdaq Challenges to Growth Potential

Updated Category News Views 35

HeartCore's Nasdaq Delisting Challenge HeartCore Enterprises, Inc. (NASDAQ:HTCR), a provider of enterprise software and consulting services, is currently facing a significant challenge related to its listing on the Nasdaq Capital Market. The company has received notice of non-compliance with the minimum bid price requirement, which mandates that its stock price must be at...

Continue Reading
Mitchell Capital Expands Portfolio with Optelos Acquisition

Updated Category News Views 236

Mitchell Capital's New Acquisition of Optelos Mitchell Capital, a prominent private equity firm, recently announced a significant acquisition that marks a pivotal moment for their long-term investment strategy. They have secured a controlling interest in Optelos, a distinguished provider of digital twin platforms that are tailored for enhancing critical infrastructure...

Continue Reading
Tampa Bay Lightning and Scripps Sports Forge Exciting Partnership

Updated Category News Views 247

Partnership Announcement Between Tampa Bay Lightning and Scripps Sports The Tampa Bay Lightning have officially entered into an exciting multi-year partnership with Scripps Sports. This collaboration signifies a new chapter for the Tampa Bay Lightning, expanding their reach in broadcasting and enhancing viewer engagement with National Hockey League (NHL) games. Through...

Continue Reading
Kazia Therapeutics Sets Meeting with FDA on Glioblastoma Treatment

Updated Category News Views 61

Kazia Therapeutics Prepares for FDA Meeting on Paxalisib Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is set to meet with the U.S. Food and Drug Administration (FDA) to explore potential pathways for the registration of its innovative drug, Paxalisib, aimed at treating newly diagnosed glioblastoma multiforme (GBM). This crucial...

Continue Reading
Important Notice for Flux Power Investors on Lead Plaintiff Claims

Updated Category News Views 100

Overview of Flux Power Investor Claims Investors with concerns regarding their investments in Flux Power Holdings, Inc. (NASDAQ: FLUX) have much to consider as recent developments unfold. The national securities law firm, Faruqi & Faruqi, LLP, is actively investigating claims that could impact investor interests and is eager to assist those affected. Critical Investment...

Continue Reading